首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Immunoreactivity of plasma parathyrin-related peptide: three region-specific radioimmunoassays and a two-site immunoradiometric assay compared.
【24h】

Immunoreactivity of plasma parathyrin-related peptide: three region-specific radioimmunoassays and a two-site immunoradiometric assay compared.

机译:血浆副甲状腺素相关肽的免疫反应性:比较了三种区域特异性放射免疫测定法和两点免疫放射测定法。

获取原文
获取外文期刊封面目录资料

摘要

We measured parathyrin (parathyroid hormone)-related peptide (PTHRP) in plasma by three region-specific RIAs and compared them with an established two-site immunoradiometric assay (IRMA) of PTHRP1-86 in samples from control subjects and from patients with primary hyperparathyroidism (PH) and humoral hypercalcemia of malignancy (HHM). The two direct RIAs of PTHRP1-34 and PTHRP37-67 were specific for regions 9-18 and 52-61, respectively. In the extraction RIA of PTHRP1-34 we used an affinity gel containing a monoclonal antibody specific for the 17-27 sequence; cross-reacting PTHRP species eluted from the gel were assayed by the RIA of PTHRP1-34. PTHRP1-86 plasma concentrations by IRMA were less than 0.23 pmol/L in control subjects and patients with PH, and were significantly increased in patients with HHM (mean 6.1 pmol/L, P less than 0.001). In contrast, plasma PTHRP1-34 concentrations were not significantly different in the three groups; in HHM patients, the mean was 190 pmol/L. Plasma PTHRP37-67 concentrations were similar in control and PH groups and, although significantly increased in HHM patients (mean 440 pmol/L, P less than 0.002), showed poor diagnostic discrimination. PTHRP1-34 concentrations after affinity extraction of plasma were also significantly higher in HHM patients (mean 10.7 pmol/L, P less than 0.001), but showed incomplete diagnostic discrimination. We conclude that the diagnostic utility of the direct RIAs for quantifying PTHRP is markedly inferior to the IRMA of PTHRP1-86.
机译:我们通过三个区域特异性RIA测量了血浆中与甲状旁腺素(甲状旁腺激素)相关的肽(PTHRP),并将其与已建立的PTHRP1-86的两点免疫放射测定法(IRMA)进行了比较,这些样本来自对照受试者和原发性甲状旁腺功能亢进症患者(PH)和恶性体液性高钙血症(HHM)。 PTHRP1-34和PTHRP37-67的两个直接RIA分别针对区域9-18和52-61。在PTHRP1-34的RIA提取中,我们使用了一种亲和凝胶,其中含有对17-27序列具有特异性的单克隆抗体。通过PTHRP1-34的RIA测定从凝胶洗脱的交叉反应PTHRP种类。对照受试者和PH患者通过IRMA测得的PTHRP1-86血浆浓度低于0.23 pmol / L,而HHM患者则显着升高(平均6.1 pmol / L,P小于0.001)。相比之下,三组的血浆PTHRP1-34浓度无显着差异。在HHM患者中,平均值为190 pmol / L。对照组和PH组血浆PTHRP37-67浓度相似,尽管在HHM患者中显着增加(平均440 pmol / L,P小于0.002),但诊断辨别力较差。 HHM患者血浆中亲和提取后的PTHRP1-34浓度也显着较高(平均10.7 pmol / L,P小于0.001),但显示出不完全的诊断区别。我们得出结论,直接RIA定量PTHRP的诊断效用明显不如PTHRP1-86的IRMA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号